$AKESO (09926.HK)$ Hong Kong stocks rose more than 8%, with a cumulative increase of more than 34% this month. As of the time of writing, the company's stock rose 8.11% to HKD 66.65, with a turnover of nearly 0.2 billion Hong Kong dollars.

On the news front, on September 8th, the clinical data of HARMONi-2 was released at the WCLC annual meeting. Akeso's PD-1xVEGF dual antibody, IBI318, achieved the main clinical endpoints of PFS in PD-L1(+)NSCLC 1L indication. Jpmorgan pointed out that the success of the global Phase III trial of this product and the confidence in gaining more market share in China have increased. Considering the upward revision of AK112 sales forecast, the bank has correspondingly raised its revenue forecast for Akeso by over 40%.

Guosen Securities pointed out that in first-line lung cancer indications, the head-to-head comparison of ivosidenib with K-drugs has achieved significant PFS superiority, and it has reached strong positivity in almost all subgroups with good safety, indicating that ivosidenib has fully demonstrated the potential of the next-generation immune checkpoint inhibitors. Ivosidenib continues to verify the potential of FIC&BIC and the company is partnering with Summit Therapeutics to advance global clinical trials. Cardunilimab and Ivosidenib have already achieved commercialization in China and are expected to become blockbuster varieties. The company's research pipeline is rich, with different molecular forms such as bispecific antibodies, antibody-drug conjugates (ADCs), and monoclonal antibodies forming a tiered portfolio.

Editor/Lambor